Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription

Stock Track

06/05

LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.

The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.

LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1135032397"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135032397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135032397?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135032397","market":"nz","top_or_hot":-1,"title":"Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription","media":"Stock Track","content":"<p>LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.</p><p>The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.</p><p>LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-05 09:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.</p><p>The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.</p><p>LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1135032397","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135032397","pubTimestamp":1780623324,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.The surge was driven by the company's highly anticipated initial public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"股票赛道|龙生物-B重磅IPO首秀获大规模超额认购盘中暴涨54.80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}